News
The FDA granted orphan drug designation to a CAR T-cell therapy for recurrent glioblastoma and high-grade astrocytomas.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback